ALUR

10-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

SCHEDULE 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

Company's recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process Allurion Technologies, Inc. (the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) that it intends to initiate delisting proceedings against Allurion after the Company was unable to demonstrate that it had regained compliance with Section 802.01B of the Listed Company Manual requiring listed companies to maintain either (i) at least $50 million in stockholders' equity or (ii) at least $50 million in total mar

8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

Allurion Technologies, Inc. (NYSE:ALUR) (the "Company" or "Allurion"), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the "January 2025 Warrants"), February 20, 2025 (the "February 2025 Warrants") and November 12, 2025 (the "November 2025 Warrants" and together with the January 2025 Warrants and the February 2025 Warrants, the "Existing Warrants"), at a reduced exercise price of $1.15 per share. The shares of common stock issuable upon exercise of the January 2025 Warra

8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

Approval provides Allurion with access to approximately 80 million Americans with obesity Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule. "Today's approval is a watershed moment for Allurion and for obesity care in the United States," said Dr. Shantanu Gaur, Founder and Chief Executive Officer. "Our goal is to deliver patients metabolically healthy weight loss by helping them lose weight, keep it off, and maintain muscle. The Allurion Smart Capsule off

5 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

5 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

Through Bionut, a leader in obesity care in Argentina, Allurion Program patients will now have access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced a partnership with Bionut, a leader in obesity care in Argentina, and Farmastar, a local pharmacy partner with access to the official supplier of Mounjaro (tirzepatide) in Argentina, to provide patients with access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule. "The obesity epidemic is growing, and patients are in need of more therapeutic options," said Romina Sapir, Di

EFFECT - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

Strong quarter-over-quarter revenue growth with continued, substantial improvement in operating expenses and operating loss Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced preliminary, unaudited results for the fourth quarter and full year 2025. Management expects preliminary, unaudited results for the period as follows: Fourth quarter revenue of $3.3 million to $3.7 million, a 22% to 37% increase quarter-over-quarter, and full-year revenue of approximately $15 million Substantial improvement in operating expenses and operating loss quarter-over-quarter and as compared to prior year "We are pleased with our results from the

S-3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

EFFECT - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

POS AM - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

8-K - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

144 - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

D - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

DEFA14A - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)